LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

EDEN

Eden Research Plc

3.90
0.25 (6.85%)
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.25 6.85% 3.90 8,648,556 16:35:18
Bid Price Offer Price High Price Low Price Open Price
3.60 3.90 3.95 3.70 3.85
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Biological Pds,ex Diagnstics 1.83 -2.24 - - 14.85
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:03 O 12,500,000 3.24 GBX

Eden Research (EDEN) Latest News (1)

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
05/6/202314:30Eden Research14,268
28/7/202204:33The sterile garden of Eden121
31/3/202214:47Eden....Onward and Upwards!50
29/3/202216:04Eden Research14
29/3/202214:36Eden Research - Who Is Behind Thallo Eco Products Corp?27

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:15:003.2412,500,000405,000.00O
16:08:033.90100,0003,900.00O
15:35:183.90562.18UT
14:55:433.803,000113.88O
14:01:423.9025,487993.99O

Eden Research (EDEN) Top Chat Posts

Top Posts
Posted at 05/6/2023 12:52 by neutralpov
EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

EDEN RESEARCH plc (EDEN.L)
Restated target SP
0.000 pence (ZERO PENCE)

Posted at 02/6/2023 10:21 by purple11
SMALL CAP IDEAS: Eden Research wins new approvals for its biopesticides... what next for its shares?

By William Farrington At Proactive Investors For This Is Money

Published: 15:25, 22 May 2023 | Updated: 15:25, 22 May 2023


Eden Research has been on a roll this year.

Flagship biopesticide products Mevalone and Cedroz have received regulatory approvals left, right and centre, gaining access to new European markets including Greece, Poland and Italy.

Mevalone was also approved in New Zealand under the brand name Novellus.

Then, in a massive boost to Eden's IP, California and Florida, the two largest US state for crop production, gave the nod to nematode killer Cedroz.
Florida recently approved Mevalone, the fungus killer mainly used in grape-growing vineyards
+1

Florida recently approved Mevalone, the fungus killer mainly used in grape-growing vineyards

Florida also approved Mevalone, the bortrytis fungus killer mainly used in grape-growing vineyards.

An impressive run of approvals no doubt, but it wasn't easy for Eden to get there.

As chief executive Sean Smith explained in a recent interview, the two-tiered regulatory system in the US was a major struggle.

Federal-level approval from the Environmental Protection Agency (EPA) was the first barrier to entry into the important market.

Typically you could expect a two-year window for approval. For Eden, it took four years to get Mevalone and Cedroz approved.

Smith pointed to Covid lockdowns as the primary cause of this massive delay

On the bright side, the EPA actually approved the products' three active ingredients and the delivery systems that will be the building blocks for future products.

In theory, this should make it easier and quicker to get new products federally approved in the US… but then you have the states to worry about.

Some, Smith explained, simply say 'thank you very much for your application and your fee, go along and do what you like'.

Others, like California, are more rigorous and demand additional field trials before approval is granted.

By far the biggest market for Eden's products and a 'significant force' in grape harvesting, California has yet to approve Eden's biggest killer app Mevalone.

'That's the next milestone for us,' stated Smith, who said to keep ears to the ground for news in the coming months.

'In the meantime, our distributors are cracking on with the job of selling products. In truth, we don't expect a major revenue impact until the 2024 growing season on the basis that California will have the most impact,' he added.

Getting in the weeds on revenue potential, it's clear that, with patience, Eden's addressable market is huge.

For Mevalone alone, European and US markets are roughly the same - around €101million and €95million ($109million and $102million) respectively, translating to around €3million of sales in each jurisdiction (slightly less in the US) per year for Eden's range of products at an estimated 40 per cent margin.

For the UK specifically, Mevalone's addressable market is relatively small compared to other regions, with the 4,000 hectares of vineyards being no bigger than France's Chablis region alone.

But that pesky, grape-loving bortrytis fungus grows 'incredibly well' on the Isles due to favourable weather conditions.

Most UK vineyard operators will cite the fungus as one of their biggest problems if you ask them, says Smith.

Approval in the UK for Mevalone is still pending, but Eden is hopeful for news some time this year.

Conversely, a country like Turkey, a massive grower of grapes to sate the country's appetite for raisins, is less of a target market due to its hot and dry conditions.

Not only do these addressable market numbers exclude additional pending approvals for Mevalone, they also exclude another huge opportunity for Eden.

As it stands, Mevalone is only approved for a few crops; primarily grapes, but apples in France too, a fruit with a similar disease profile to grapes.

But just as Viagra, to use a crude example, was originally intended for heart disease before rising to the challenge in other medicinal fields, Mevalone has significant potential to branch out into other use cases.

It's called 'label expansion' in pharma parlance, described by the FDA as when 'additional clinical data have shown the drug can safely and effectively treat patient populations other than those for which it was originally intended'.

In Eden's situation, this means discovering new use cases far beyond what Mevalone is currently approved for.

Smith explains: 'The target that we are jointly focused on right now together is to expand the label to include two other disease targets, which will mean that the target market multiplies by size by a factor of 10.'

Clearly massive potential, and Eden has already made steps in expanding Mevalone's label, including an application in France in the coming weeks.

Not enough expansion plans on the plate for you? There's also an entirely new product in the works being developed in partnership with US agriscience giant Corteva.

'We've been working with those guys for the last few years on the development of a seed treatment, and we are expecting to have a lot more to say about that fairly soon,' Smith teased.

Future sales potential for this as yet unnamed seed treatment is €21.6million in the US and €8.6million in the UK and Europe.

As it stands, Eden's share price has underperformed in 2023, with, at 3.4p, a market capitalisation of £14million.

But it's hard to deny the potential of the group, even if, as with regulatory approvals, it may require a bit of patience.

Keep your eyes peeled.

Posted at 01/6/2023 12:42 by supersonico
BRUCIE,
Caution and cynicism has historically been a wise way to approach investing in EDEN. The TT back to school is a case study in cautionary lessons.
However..I believe we're in a very different phase of Eden's evolution now and it's Ecovelex Corteva not TT who are driving this..the contrast between the two is vast.

Yesterdays post by Igor Teslenko President EMEA at Corteva indicates to me whether money is coming sooner in preparation for the 2024 growing season or in 18-24 months time. It's a gamble, it always has been but my biased dots, and there are many, point to the 2024 season which means under some sort of 'emergency' provision similar to what we have seen in Italy, Pioneer prepare Ecovelex this summer ready for farmers orders from December onwards for spring planting. This way I imagine Eden get paid this year and a cash call is avoided.

I'd also not be surprised by a Corteva strategic investment Sipcam style but that would only enhance the 2023 money position despite any dilution. AWGATWT.
.............................................................

'Recent regulatory changes in the EU have left farmers without conventional approaches to combating crop damage caused by birds. Corteva Agriscience, together with Eden Research plc, have responded with agility and speed to fill this gap left in the market with a sustainable alternative.

Together we have developed Ecovelex™, a seed treatment based on plant-derived chemistry that is a safe deterrent for birds.

This plant-derived innovation is offputting to birds due to its unpleasant taste and smell, leaving the bird unharmed, along with farmers' crops.

I am delighted to see the efforts of our open collaboration approach come to fruition with the rapid development of this solution completed over three years.

The journey from R&D laboratories to farms across Europe continues, as Eden has applied for its authorization in Europe with Corteva as its distribution partner.'

hTTps://www.linkedin.com/in/igor-teslenko-%F0%9F%87%BA%F0%9F%87%A6-3a9965a/

Posted at 29/5/2023 10:16 by supersonico
ravenna23 vs supersonico

'Stop peddling false hopes' and other Lube BS.

''''''''''''''''''''''''''''''''''''''
'ravenna23 - 22 Mar 2023 - 11:05:04 - 13846 of 14133 Eden Research - EDEN
It really is sad to observe individuals who cannot admit they have made an investment mistake. All this talk of whales is delusional. If they do buy in small investors will be diluted to nothing. Stop peddling false hopes'.
'''''''''''''''''''''''''''''''''

So lets examine where the facts or 'false hopes' as Lube describe from supersonico are being stated; .....

From around 6mins Sean Smith talks I assume about the regulatory problem whales have had with neonicotinoids then goes on to talk about the insecticide trials of either Corteva or Whale2/3/4..he has previously talked about 'multiple interested parties' (10 January 2023)


"That product is currently under going field trials with potential partners in fact I'm very pleased to say one of those partners is running in excess of 80 different field trials this year".

hTTps://www.youtube.com/watch?v=j9xMFQJJQnw

...............................................................................
supersonico - 09 Feb 2023 - 10:21:02 - 13759 of 14133 Eden Research - EDEN
Annual Insecticide / development update...2019-2023

15 January 2019;
The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging.


14 January 2020
Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaine├Ą encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture."

11 February 2021
Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients.

2nd March 2022
Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden.


10 January 2023
Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work.

Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results.
The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US.

Posted at 25/5/2023 13:29 by investingisatrickygame
Mevalone and Cedroz approvals from the US to New Zealand

Strategic partner, Sipcam, invested in Eden, trading 77 years and T/O $650 million
Source: hxxps://www.sipcam-oxon.com/en/who-we-are

Corteva www.corteva.com/ T/O $18 Billion, $9 billion in seeds, number one seed brand in the world - Pioneer

Eden & Corteva hxxps://polaris.brighterir.com/public/eden_research/news/rns/story/x5dpn0w So this seed and the possibility of other products

We are due a regulatory submission and an investor update

Insecticide "This excludes the opportunities for bioinsecticides which are estimated to be worth an additional €237 million." purely in regard to the US where Eden's AI's and Sustaine technology are already approved, so one might assume a more speedy approval for Eden's in-house insecticide. Also, "and the first sales of our insecticides in the US in 2024/2025"

Source: hxxps://polaris.brighterir.com/public/eden_research/news/rns/story/w69v69w

The days of moaning about Eden by a few are coming to an end. Carry on if they will, but the more than positive writing is on the wall and the share price will correct itself accordingly. If it doesn't, for any bizarre reason, Eden will get taken out cheaply once the seed and insecticide are approved. That is my opinion.

Posted at 05/5/2023 12:55 by supersonico
Oh come on Investing ..you can't be serious.

Surely these three questionable staff-what-staff Lube statements all can't be wrong?

'Therefore my best guess at zero pence is June 30th'.

'However I expect Eden to delist and go private before then'.

'If that fails it will be a prepackaged administration which will end up with the biggest shareholders and Corteva owning Eden'.


ravenna23 - 13 Jan 2023 - 13:31:40 - 13657 of 13962 Eden Research - EDEN
In order to survive 2023 at the current rate of cash burn, Eden must raise funds before the year end accounts are published. If they fail to do so the new auditor must qualify the accounts on a going concern basis. They can delay accounts until end June but this will earn them another black mark with the regulator. Therefore my best guess at zero pence is June 30th. However I expect Eden to delist and go private before then. If that fails it will be a prepackaged administration which will end up with the biggest shareholders and Corteva owning Eden.
Krill are not chill.

Posted at 26/4/2023 18:11 by supersonico
NUMBER OF AIM SECURITIES IN ISSUE
As of 21 March 2023, the number of shares in issue was 380,858,607.

SIGNIFICANT SHAREHOLDERS
As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were:


Name

Number of shares

% of the issued ordinary share capital

BGF Investment Management Limited
51,733,000
13.58%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
31,737,596
8.33%

Gresham House Asset Management Limited
27,845,445
7.31%


Interactive Investor
25,172,555
6.61%

Canaccord Genuity Group Inc
22,584,000
5.93%

JM Finn Nominees Limited
19,839,762
5.21%

Atul Unadkat
18,117,567
4.76%

Rathbone Nominees Limited
15,621,872
4.10%

HSBC Global Custody Nominee (UK) Limited
13,066,384
3.43%



Name
Number of shares
% of the issued ordinary share capital

A Abrey
1,620,346
0.43%

L van der Broek
929,500
0.24%

S Smith
911,039
0.24%

R Cridland
130,167
0.03%


SHARES NOT IN PUBLIC HANDS
In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands.

.................................................................................

Atul keeps buying.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%

hTTps://www.edenresearch.com/investors/securities_information.aspx

Posted at 05/4/2023 13:54 by investingisatrickygame
Supersonico is right. it doesn't take much research and qualification, if you so choose. If you don't choose, then you won't understand.

Thereafter, it is a matter of faith. Super clearly has it!

hxxps://polaris.brighterir.com/public/eden_research/news/rns/story/xlgkmpr

"The seed treatment market is globally worth approximately US$6.5 billion annually with an estimated annual growth rate of between 10 and 12 percent. Eden estimates product sales arising from the successful development and registration of this seed treatment product may reach €20m per year in the short term following launch with significant opportunities for growth in excess of this figure."

hxxps://polaris.brighterir.com/public/eden_research/news/rns/story/r7n0yvw

"Further trials will be undertaken under a one-year evaluation agreement and, subject to the results, Corteva Agriscience and Eden will look to sign a distribution agreement for the EU, Russia, Ukraine and Turkey giving Eden the opportunity to capture a significant share of this market. The Directors estimate that, if successful, there is the opportunity to generate up to c. €40 million of revenue for Eden from European geographies alone (current market) from this product."

8/03/2023 Trading Update Presentation

hxxps://www.edenresearch.com/_userfiles/pages/files/r2023/230301_eden_trading_update_presentation.pdf

Posted at 05/4/2023 12:29 by kenmitch
Investor ignorance and lack of proper research supersonico? Really? Why then is the share price down 98%? Doesn’t that suggest that competent investors realised years ago that Eden was a sell, not least because of such tiny revenues, and that those still convinced are in a tiny minority.

If there really was a WHALE Eden would be shouting it from the rooftops as it would give the share price a lift and make a successful fund raising more likely too and at a better price.

The time to buy EDEN would be when there are signs at long long last of sales starting to take off. I keep an eye on it and all EDEN’s updates just in case. It’s because they haven’t got any sales despite all the approvals that the share has crashed, and deservedly so.

Without increasing sales soon, and if they can’t find yet more mug investors to support yet another fund raise, EDEN will go the way of ENRT, originally from the same stable, and go bust. ENRT also had fans convinced to the bitter end!

Posted at 23/1/2023 12:17 by neutralpov
The delusional or lying gang of rampers pokes its collective nose out above - and, hahahaha - the share price responds accordingly.

Down the plughole she goes! ;D

Reiterated and restated and reaffirmed and rechecked TARGET Share Price
EDEN Research plc (EDEN)
0.0000 p (ZERO pence)

(popcorn)

Eden Research share price data is direct from the London Stock Exchange
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230605 16:52:01